Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KILAUEA: Episcleral Brachytherapy for PCV
NCT05251636Phase 3Not yet recruiting
- Sponsor
- Salutaris Medical Devices
- Start
- Mar 2025
- Primary completion
- Sep 2026
01
Overview
Phase 3, randomised, double-blind trial in polypoidal choroidal vasculopathy (PCV) (2 arms), sponsored by Salutaris Medical Devices. Primary endpoint: Best Corrected Visual Acuity at 12 months. Planned start Mar 2025; status: not yet recruiting.
02
Conditions
polypoidal choroidal vasculopathy (PCV)
Beyond the preview
Go deeper on NCT05251636.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05251636.